Patients aged 45–64 years (30.08%) also accounted for a high proportion, which may be associated with the high frequency that patients with NSCLC harboring the EML4-ALK fusion gene were observed in relatively younger patients (Baldi et al., 2014; Toyokawa and Seto, 2014). This evidence concerns the gene EML4 and non-small cell lung carcinoma.